29 March 2022>: Meta-Analysis
The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis
Jian Chen 1ABCDEF , Xudong Li 2BCD , Ruihao Liu 1DEF , Yufen Xie 1DE , Zhigao Liu 1CE , Haiwei Xiong 1CE , Yingliang Li 1ACG*DOI: 10.12659/MSM.935671
Med Sci Monit 2022; 28:e935671
Table 2 Characteristics of the included studies.
Author | Year | Cancer-type | Country | Ethnicity | Control source | Genotype method | Case | Control | HWE (Control) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Garcia-Closas | 2013 | Breast cancer | Multi-center | Caucasian | Mixed | Illumina array | 3318 | 2637 | 557 | 22825 | 15798 | 2828 | 0.412 |
JB Liu | 2013 | Breast cancer | China | Asian | PB | PCR-RFLP | 733 | 67 | 0 | 686 | 111 | 3 | 0.801 |
JB Liu | 2013 | Breast cancer | China | Asian | PB | PCR-RFLP | 278 | 22 | 0 | 501 | 96 | 3 | 0.782 |
LQ Zhou | 2013 | ESCC | China | Asian | PB | PCR-RFLP | 501 | 37 | 2 | 478 | 70 | 2 | 0.946 |
LQ Zhou | 2013 | ESCC | China | Asian | PB | PCR-RFLP | 529 | 56 | 3 | 510 | 88 | 2 | 0.679 |
CB Fan | 2014 | NHL | China | Asian | PB | PCR-RFLP | 187 | 13 | 0 | 346 | 53 | 1 | 0.785 |
JB Feng | 2014 | Gastric cancer | China | Asian | HB | PCR-RFLP | 208 | 209 | 51 | 210 | 219 | 64 | 0.845 |
Gansmo | 2015 | Breast cancer | Norway | Caucasian | PB | LightSNiP assay | 966 | 643 | 108 | 1021 | 703 | 146 | 0.271 |
Gansmo | 2015 | Colon cancer | Norway | Caucasian | PB | LightSNiP assay | 823 | 600 | 108 | 2042 | 1439 | 266 | 0.848 |
Gansmo | 2015 | Lung cancer | Norway | Caucasian | PB | LightSNiP assay | 715 | 515 | 101 | 2042 | 1439 | 266 | 0.848 |
Gansmo | 2015 | Prostate cancer | Norway | Caucasian | PB | LightSNiP assay | 1412 | 927 | 161 | 1021 | 736 | 120 | 0.271 |
F Gao | 2015 | Lung cancer | China | Asian | PB | PCR-RFLP | 297 | 22 | 1 | 548 | 90 | 2 | 0.701 |
F Gao | 2015 | Lung cancer | China | Asian | PB | PCR-RFLP | 183 | 17 | 0 | 321 | 77 | 2 | 0.514 |
Pedram | 2016 | Breast cancer | Iran | Caucasian | HB | T-ARMS-PCR assay | 123 | 87 | 10 | 165 | 81 | 14 | 0.061 |
Gansmo | 2016 | Ovarian cancer | Norway | Caucasian | PB | LightSNiP assay | 716 | 564 | 105 | 1021 | 703 | 146 | 0.271 |
Gansmo | 2016 | Endometrial cancer | Norway | Caucasian | PB | LightSNiP assay | 757 | 541 | 106 | 1021 | 703 | 146 | 0.271 |
Khanlou | 2017 | Thyroid cancer | Iran | Caucasian | HB | T-ARMS-PCR assay | 63 | 34 | 5 | 144 | 76 | 12 | 0.893 |
Hashemi | 2018 | Breast cancer | Iran | Caucasian | HB | T-ARMS-PCR assay | 175 | 83 | 7 | 142 | 70 | 9 | 0.995 |
Pedram | 2020 | Breast cancer | Iran | Caucasian | PB | T-ARMS-PCR assay | 114 | 82 | 10 | 120 | 68 | 11 | 0.946 |
DM Zhao | 2020 | Colorectal cancer | China | Asian | HB | MassARRAY | 304 | 128 | 11 | 323 | 180 | 25 | 1.000 |
Kotarac | 2020 | Prostate cancer | Serbia | Caucasian | HB | TaqMan | 198 | 131 | 23 | 182 | 144 | 31 | 0.890 |
Tripon | 2020 | AML | Romania | Caucasian | HB | T-ARMS-PCR assay | 202 | 144 | 57 | 209 | 114 | 83 | |
CG Song | 2012 | Breast cancer | China | Asian | HB | MassArray | 53 | 57 | 14 | 44 | 43 | 14 | 0.802 |
YW Zhang | 2012 | NPC | China | Asian | PB | RT-PCR | 98 | 91 | 21 | 90 | 88 | 22 | 0.998 |
Thunell | 2014 | Hereditary melanoma | Sweden | Caucasian | PB | RT-PCR | 27 | 21 | 2 | 389 | 340 | 70 | 0.940 |
HP Yu | 2011 | SCCHN | America | Caucasian | HB | TaqMan | 487 | 477 | 111 | 518 | 455 | 106 | 0.917 |
HP Yu | 2012 | SCCHN | America | Caucasian | HB | TaqMan | 170 | 158 | 43 | 150 | 135 | 36 | 0.798 |
GC Wu | 2015 | Gastric cancer | China | Asian | HB | TaqMan | 188 | 281 | 173 | 212 | 290 | 218 | |
MY Wang | 2017 | Gastric cancer | China | Asian | HB | TaqMan | 487 | 493 | 97 | 552 | 485 | 136 | 0.180 |
Hashemi | 2018 | Breast cancer | Iran | Caucasian | HB | T-ARMS-PCR assay | 86 | 151 | 26 | 44 | 142 | 27 | |
FH Yu | 2019 | Retinobla-stoma | China | Asian | HB | TaqMan | 77 | 39 | 10 | 71 | 59 | 18 | 0.426 |
HP Yu | 2011 | SCCHN | America | Caucasian | HB | TaqMan | 684 | 351 | 40 | 665 | 376 | 38 | 0.229 |
HP Yu | 2012 | SCCHN | America | Caucasian | HB | TaqMan | 118 | 179 | 74 | 202 | 109 | 10 | 0.589 |
MY Wang | 2017 | Gastric cancer | China | Asian | HB | TaqMan | 380 | 539 | 158 | 449 | 532 | 192 | 0.271 |
Hashemi | 2018 | Breast cancer | Iran | Caucasian | HB | T-ARMS-PCR assay | 183 | 75 | 6 | 164 | 50 | 4 | 0.997 |
FH Yu | 2019 | Retinobla-stoma | China | Asian | HB | TaqMan | 39 | 49 | 38 | 57 | 64 | 27 | 0.491 |
HP Yu | 2011 | SCCHN | America | Caucasian | HB | TaqMan | 307 | 545 | 223 | 296 | 552 | 231 | 0.677 |
HP Yu | 2012 | SCCHN | America | Caucasian | HB | TaqMan | 233 | 126 | 12 | 93 | 156 | 72 | 0.913 |
MY Wang | 2017 | Gastric cancer | China | Asian | HB | TaqMan | 547 | 447 | 83 | 604 | 462 | 107 | 0.393 |
ESCC – esophageal squamous cell carcinoma; NHL – non-Hodgkin lymphoma; NPC – nasopharyngeal cancer; SCCHN – squamous cell carcinoma of the head and neck; AML – acute myeloid leukemia. |